Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Robert A. Dillman"'
Publikováno v:
Human Vaccines & Immunotherapeutics.
Autor:
Gabriel I. Nistor, Robert O. Dillman, Rockelle M. Robles, James L. Langford, Aleksandra J. Poole, Muchlis A. U. Sofro, Yetty M. Nency, Jonny Jonny, Martina L. Yana, Mahammad Karyana, Endang S. Lestari, Ria Triwardhani, Mujahidah Mujahidah, Retty K. Sari, Nur A. Soetojo, Djoko Wibisono, Daniel Tjen, Taruna Ikrar, Gregory Sarkissian, Haryono Winarta, Terawan A. Putranto, Hans S. Keirstead
Publikováno v:
Human vaccinesimmunotherapeutics. 18(6)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a world-wide pandemic. Internationally, because of availability, accessibility, and distribution issues, there is a need for additional vaccines. This study aimed to: establish t
Publikováno v:
Human Vaccines & Immunotherapeutics
This report describes efforts to understand the immune mechanism of action that led to a complete response in a patient with progressive, refractory, metastatic melanoma after treatment with a therapeutic vaccine consisting of autologous dendritic ce
Autor:
Thomas H. Taylor, Renato V. LaRocca, Daniela A. Bota, Jose Carrillo, Mehrdad Abedi, Robert O. Dillman, David Piccioni, Xiao-Tang Kong, Candace Hsieh, Gabriel Nistor, Christopher Duma, Robert Aiken, Santosh Kesari, Frank P.K. Hsu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundStandard therapy of glioblastoma (GBM), which includes maximum safe resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, is associated with poor overall survival (OS). Adding treatment
Autor:
Renato V. LaRocca, Frank P.K. Hsu, Robert O. Dillman, Christopher Duma, Candace Hsieh, Santosh Kesari, Gabriel Nistor, Mehrdad Abedi, David Piccioni, Thomas H. Taylor, Jose Carrillo, Robert Aiken, Xiao-Tang Kong, Daniela A. Bota
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundStandard aggressive therapy of glioblastoma (GBM), which includes maximum safe resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, is associated with a 25% 2-year overall survival (OS)
Autor:
Charles G. Drake, Walter J. Urba, David Kaufman, Leisha A. Emens, Jeffrey S. Weber, Alessandra Cesano, Douglas G. McNeel, Ana C. Anderson, Marcela V. Maus, Mario Sznol, Jon M Wiggington, Lisa H. Butterfield, Patrick Hwu, David Parkinson, Ernest C. Borden, James L. Gulley, Michael J. Mastrangelo, Michael B. Atkins, Kim Margolin, Julie R. Brahmer, Thomas F. Gajewski, Robert O. Dillman, Pedro Romero, Daniel S. Chen, Francesco M. Marincola, George J. Weiner, Paolo A. Ascierto, Tanja D. de Gruijl, Michael T. Lotze, Paul M. Sondel, F. Stephen Hodi, Bernard A. Fox, Stefani Spranger, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for immunotherapy of cancer, vol. 8, no. 1
Ascierto, P A, Fox, B, Urba, W, Anderson, A C, Atkins, M B, Borden, E C, Brahmer, J, Butterfield, L H, Cesano, A, Chen, D, De Gruijl, T, Dillman, R O, Drake, C G, Emens, L A, Gajewski, T F, Gulley, J L, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, D G, Margolin, K, Marincola, F, Mastrangelo, M J, Maus, M V, Parkinson, D R, Romero, P J, Sondel, P M, Spranger, S, Sznol, M, Weiner, G J, Wiggington, J M & Weber, J S 2020, ' Insights from immuno-oncology : The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 ', Journal for Immunotherapy of Cancer, vol. 8, no. 1, e000878 . https://doi.org/10.1136/jitc-2020-000878
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
Journal for immunotherapy of cancer, vol. 8, no. 1
Ascierto, P A, Fox, B, Urba, W, Anderson, A C, Atkins, M B, Borden, E C, Brahmer, J, Butterfield, L H, Cesano, A, Chen, D, De Gruijl, T, Dillman, R O, Drake, C G, Emens, L A, Gajewski, T F, Gulley, J L, Stephen Hodi, F, Hwu, P, Kaufman, D, Kaufman, H, Lotze, M, McNeel, D G, Margolin, K, Marincola, F, Mastrangelo, M J, Maus, M V, Parkinson, D R, Romero, P J, Sondel, P M, Spranger, S, Sznol, M, Weiner, G J, Wiggington, J M & Weber, J S 2020, ' Insights from immuno-oncology : The Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 ', Journal for Immunotherapy of Cancer, vol. 8, no. 1, e000878 . https://doi.org/10.1136/jitc-2020-000878
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer
The hypoxia and profound inflammatory response associated with the pneumonitis observed with the severe acute respiratory virus coronavirus-2 (SARS-COV-2) virus responsible for the recent COVID-19 pandemic has overwhelmed intensive care facilities in
Autor:
Andrew N. Cornforth, Carol DePriest, Gabriel Nistor, Edward F. McClay, Robert O. Dillman, Thomas Amatruda
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Despite improved survival following checkpoint inhibitors, there is still a potential role for anti-cancer therapeutic vaccines. Because of biological heterogeneity and neoantigens resulting from each patient’s mutanome, autologous tumor
Autor:
Candace Hsieh, Robert O. Dillman, Frank P.K. Hsu, Gabriel Nistor, David Piccioni, Christopher Duma, Santosh Kesari, Jose Carrillo, Robert Aiken, Thomas H. Taylor, Daniela A. Bota, Xiao-Tang Kong, Renato V. LaRocca, Mehrdad Abedi
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A358-A358
BackgroundDespite standard aggressive therapy (maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ), then maintenance TMZ), 2-year survival is only about 25% for patients with newly diagnosed primary gl
Autor:
Gabriel Nistor, Xiang-Tang Kong, Thomas H. Taylor, David Piccione, Robert O. Dillman, Jose Carrillo, Candace Hsieh, Christopher Duma, Daniela A. Bota, Santosh Kesari, Robert Aiken, Renato V. LaRocca, Mehrdad Abedi, Frank P.K. Hsu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundFor patients with newly diagnosed primary glioblastoma (GBM), maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ results in a 2-year survival of only 25%. Adding
Autor:
Thomas H. Taylor, Candace Hsieh, Xiao-Tang Kong, Frank P.K. Hsu, Gabriel Nistor, Christopher Duma, Santosh Kesari, Jose Carrillo, Aleksandra J. Poole, David Piccioni, Daniela A. Bota, Renato V. LaRocca, Mehrdad Abedi, Robert Aiken, Robert O. Dillman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundDespite standard aggressive therapy, including maximum safe surgical resection, concurrent radiation therapy and temozolomide chemotherapy (RT/TMZ) followed by maintenance TMZ, survival is still extremely poor for patients with newly diagno